Lemon Bottle

• Defensible research value is limited to authenticity testing, supply-chain and label verification, multi-ingredient assay development, undeclared-substance screening, formulation characterization and comparison of regulatory evidence
• No fat-loss, body-contouring, metabolic or skin-tightening benefit has been established for an independently qualified injectable formulation.

CAS

83-88-5

Formula

Not applicable — mixture or multi-component material

Molecular weight

Component-specific; no single molecular weight

Appearance

Lot-specific aqueous material; colour or clarity cannot establish authenticity, composition, sterility or suitability

Purity

Component-wise specification; confirm on released-lot COA · target, verify batch COA

Storage

Follow only independently verified released-lot labelling and stability data for the authenticated product and intended research use. Distributor room-temperature or after-opening advice does not establish identity, microbiological quality or stability of another source. Quarantine temperature excursions and any lot lacking traceable storage conditions.

MOQ

On request

Lead time

Confirmed with quote

Lemon Bottle is a trade name used for multi-ingredient aqueous products and is not a peptide or single defined substance. FDA warning letters dated March 3, 2025 identified LemonBottle Ampoule Solution sold with injectable fat-loss claims as an unapproved new drug. Swissmedic classified injection-labelled products as unauthorized medicines and reported major declaration mismatches among samples from different sources: one contained only caffeine and another contained none of the listed ingredients. The distributor later stated it could not verify those samples as original and that its original product is an external-use cosmetic, not intended for injection. Product name, packaging or a cosmetic registration therefore cannot establish authenticity, composition or injectable quality.

• Appropriate laboratory contexts include authentication, quantitative composition, undeclared-ingredient screening, container and stability studies, particulate and microbiological method development, and comparison of label claims with regulator findings
• No approved clinical indication exists.

No verified in-vivo mechanism exists for a standardized Lemon Bottle formulation because composition and authenticity are not reliably established and no qualifying clinical study of a fixed blend was identified. Mechanistic statements about riboflavin, lecithin or bromelain describe individual ingredients or marketing hypotheses and cannot prove fat-cell disruption by the traded product. It must not be equated with deoxycholic acid or Kybella, a different, specifically regulated finished drug.

• Not for human or veterinary administration
• FDA warns that unapproved fat-dissolving injections have been associated with permanent scarring, serious infection, skin deformity, cysts and deep painful nodules, and its 2025 warning letters identified LemonBottle Ampoule Solution as an unapproved new drug
• Swissmedic advises against use and reported falsified or mismatched sampled products
• Unknown composition, injectable marketing and absent validated sterility or endotoxin controls create substantial and unresolved risk.

Interactions reported in the literature

• No human combination, compatibility or injection-site guidance applies
• Do not combine this material with deoxycholic acid, phosphatidylcholine, fillers, botulinum toxin or other body-contouring products
• Laboratory mixture studies require authenticated components, single-component controls and component-resolved analytics.

Lemon Bottle10 mL · WHJLP-LB10-260323-D

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

• Treat product identity as unverified until an authenticated supply chain and independent testing agree
• Require manufacturer/distributor authorization, lot traceability, tamper evidence, full quantitative composition, orthogonal identity and assay for declared ingredients, broad undeclared-substance screening, pH, osmolality where relevant, particulates, container integrity and stability
• If microbiological limits, endotoxin or sterility are required, each needs a validated method, acceptance limit and released-lot result
• Cosmetic registration, clear appearance, a generic COA or ingredient list is insufficient.

Follow only independently verified released-lot labelling and stability data for the authenticated product and intended research use. Distributor room-temperature or after-opening advice does not establish identity, microbiological quality or stability of another source. Quarantine temperature excursions and any lot lacking traceable storage conditions.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

• Primary regulatory sources: FDA Amazon warning letter MARCS-CMS 695821 dated March 3, 2025, which identifies LemonBottle Ampoule Solution with injectable fat-loss claims as an unapproved new drug; FDA consumer guidance on harms from unapproved fat-dissolving injections; and Swissmedic’s March 26, 2024 warning plus June 25, 2024 addendum describing sample mismatches and the distributor’s external-use-only position. Marketing, sales-volume and clinic protocol claims were removed from the decision content.

1. 01

   Dermal Necrosis and Chronic Abscess Formation Following Fat Dissolving Injections Administered by a Non-Medical Practitioner: A Case Report

   OSF Preprints (Center for Open Science) · 2026 · case report (preprint, not yet peer-reviewed)

   Open source
2. 02

   Swissmedic issues warning about the illegal medicinal product "Lemon Bottle" lipolysis solution

   Swissmedic (Swiss national medicines regulatory authority) · 2024 · regulatory document / national medicines-agency public warning

   Open source
3. 03

   Using Fat-Dissolving Injections That Are Not FDA Approved Can Be Harmful

   U.S. Food and Drug Administration (FDA) · 2024 · regulatory document / consumer safety communication

   Open source
4. 04

   Fox Pharma LLC — Warning Letter 699225

   U.S. Food and Drug Administration (FDA), Office of Compliance · 2025 · regulatory document / FDA enforcement warning letter

   Open source
5. 05

   Urgent regulation of fat injections, fillers and botox needed

   Chartered Trading Standards Institute (UK) · 2025 · industry/professional body statement

   Open source